The Conversation (0)
GeoVax Labs announced their chief scientific officer, Dr. Farshad Guirakhoo presented the company’s results in its studies of their NS-1 based Zika vaccine.
GeoVax Labs (OTCQB:GOVX) announced their chief scientific officer, Dr. Farshad Guirakhoo presented the company’s results in its studies of their NS-1 based Zika vaccine.
As quoted in the press release:
Dr. Guirakhoo delivered the talk, entitled “A Novel Alternative Approach to Develop a Safe Vaccine for Zika,” today during the Advances in Vaccine Technologies session at the Immuno-Oncology Summit in Boston, MA.
Dr. Guirakhoo presented research showing that a single dose of GeoVax’s Zika vaccine gave 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the first report of i) a Zika vaccine based on the ZIKV NS1 protein, and ii) single-dose full protection against ZIKV using an immunocompetent lethal mouse challenge model.
Click here to read the full press release.
Source: www.marketwired.com